← Back to Search

Cell Therapy

Gastrin + Islet Transplant for Type 1 Diabetes

Phase 1 & 2
Recruiting
Led By Fouad Kandeel, MD, PhD
Research Sponsored by City of Hope Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18-68 years
Type 1 diabetes mellitus for at least 5 years (documented with fasting C-peptide level of </= 0.2 ng/ml before and </= 0.3 ng/ml after IV administration of 1 mg of glucagon)
Must not have
Evidence of active peptic ulcer disease
Previous organ/tissue transplant
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will evaluate if the combination of these two products can help patients with type 1 diabetes who have difficulty controlling their blood sugar levels with insulin make insulin again and improve blood sugar control.

Who is the study for?
This trial is for adults aged 18-68 with type 1 diabetes who have unstable blood glucose, frequent hypoglycemia, or severe episodes leading to hospital visits. Participants must be fully vaccinated against COVID-19 and willing to follow a strict post-transplant regimen including immunosuppression and contraception. Exclusions include active peptic ulcers, untreated psychiatric illness, significant cardiovascular disease, high insulin requirements, certain infections like HIV/HBV/HCV/CMV/syphilis, recent organ transplants, and those without insurance for follow-up care.
What is being tested?
The study tests the safety and effectiveness of Gastrin hormone treatment combined with transplantation of human allogenic islet cells in patients with difficult-to-control type 1 diabetes. These experimental treatments aim to help patients produce their own insulin again and improve blood sugar control.
What are the potential side effects?
Potential side effects may include reactions related to the immune system due to the introduction of foreign cells (transplanted islets) such as inflammation or infection risks from immunosuppressive drugs required after transplant. Specific side effects of Gastrin are not detailed but could involve digestive system disturbances given its role in gut hormone secretion.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 68 years old.
Select...
I have had Type 1 diabetes for over 5 years with specific C-peptide levels.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I currently have an active stomach ulcer.
Select...
I have had an organ or tissue transplant.
Select...
I have anemia or another blood disorder needing treatment.
Select...
I use more than 1 unit of insulin per kilogram of my body weight daily.
Select...
I have a high risk of bleeding or am on long-term blood thinners.
Select...
I am on long-term medication for a chronic illness that cannot be used with the trial drugs.
Select...
My blood pressure is high (140/90 or more) despite taking medication.
Select...
My kidney function is low, and I have high levels of protein in my urine.
Select...
I have an eye condition where new blood vessels are growing abnormally.
Select...
I do not have serious heart or blood vessel diseases that can't be fixed with surgery.
Select...
My cholesterol or triglycerides are high despite treatment.
Select...
I do not have any current severe infections or long-term infections like TB, HIV, or hepatitis.
Select...
My health insurance does not cover post-study care costs.
Select...
I have had a gastric bypass surgery.
Select...
My liver function tests are not normal, or I have serious liver or gallbladder issues.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Single Arm StudyExperimental Treatment2 Interventions

Find a Location

Who is running the clinical trial?

City of Hope Medical CenterLead Sponsor
605 Previous Clinical Trials
1,923,585 Total Patients Enrolled
University of California, Los AngelesOTHER
1,568 Previous Clinical Trials
10,314,252 Total Patients Enrolled
Fouad Kandeel, MD, PhDPrincipal InvestigatorCity of Hope Medical Center
2 Previous Clinical Trials
55 Total Patients Enrolled

Media Library

Allogenic Human Islet Cells (Cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT03746769 — Phase 1 & 2
Type 1 Diabetes Research Study Groups: Single Arm Study
Type 1 Diabetes Clinical Trial 2023: Allogenic Human Islet Cells Highlights & Side Effects. Trial Name: NCT03746769 — Phase 1 & 2
Allogenic Human Islet Cells (Cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03746769 — Phase 1 & 2
~3 spots leftby Feb 2026